10-Q: Altria Q3 2025: E-Vapor Impairment Hits Earnings

Altria Group, Inc. reports a significant decline in Q3 2025 net earnings and EPS due to a goodwill impairment charge in its e-vapor unit, despite adjusted earnings growth.

Summary

• Net earnings for the nine months ended September 30, 2025, decreased by 29.1% to $5,830 million from $8,225 million in the prior year.
• Diluted EPS for the nine months decreased by 27.4% to $3.45 from $4.75.
• Adjusted net earnings for the nine months increased by 3.6% to $6,966 million, and adjusted diluted EPS increased by 5.9% to $4.12.
• Net revenues for the nine months decreased by 3.4% to $17,433 million, primarily due to lower smokeable products segment volume.
• A non-cash goodwill impairment of $873 million was recorded for the e-vapor reporting unit in Q1 2025 due to lower projected volume and revenue from NJOY ACE's removal from the U.S. market and higher commercialization costs for future products.
• The Board approved a 3.9% increase in the quarterly dividend rate to $1.06 per share, making the annualized rate $4.24 per share.
• The share repurchase program was expanded by $1.0 billion to $2.0 billion, expiring December 31, 2026.
• Net cash provided by operating activities increased to $6,019 million for the nine months ended September 30, 2025, from $5,413 million in the prior year.
• Domestic cigarette shipment volume decreased by an estimated 10.5% (adjusted) for the nine months and 9% (adjusted) for the three months.
• Marlboro's share of the premium cigarette segment increased by 0.2 share points to 59.5% for the nine months.
• Oral tobacco products segment net revenues increased by 0.6% for the nine months, but decreased by 4.6% for the three months due to lower volume/mix.
• The U.S. nicotine pouch category grew to 55.7% of the U.S. oral tobacco category in Q3 2025, an increase of 11.1 share points year-over-year.
• On! nicotine pouch share of the nicotine pouch category decreased by 2.1 share points to 16.6% for the nine months and 4.1 share points to 15.6% for the three months.
• Altria is appealing the ITC's exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States.
• The U.S. District Court for the Eastern District of Virginia ruled in favor of the IRS regarding foreign attribution rules, leading to a $310 million reserve for 2018-2025 tax years and a $77 million increase to a valuation allowance.

Sentiment

Score: 4

Explanation: While adjusted earnings and EPS showed growth, reported net earnings and EPS declined significantly due to a substantial e-vapor goodwill impairment. Key product volumes (cigarettes, MST) are declining, and the company is losing share in the growing nicotine pouch category. Regulatory and litigation challenges, particularly the NJOY ACE import ban and adverse tax ruling, present ongoing headwinds. The dividend increase and share repurchase expansion are positive but are overshadowed by the operational and legal challenges.

Positives

• Adjusted net earnings increased by 3.6% and adjusted diluted EPS increased by 5.9% for the nine months ended September 30, 2025.
• The quarterly dividend rate increased by 3.9% to $1.06 per share, resulting in an annualized rate of $4.24 per share.
• The share repurchase program was expanded by $1.0 billion to $2.0 billion, demonstrating commitment to shareholder returns.
• Net cash provided by operating activities increased to $6,019 million for the nine months, up from $5,413 million in the prior year, indicating strong operational cash generation.
• Marlboro's share of the premium cigarette segment increased by 0.2 share points to 59.5% for the nine months, showing strength in its flagship brand.
• The total oral tobacco products category industry volume increased by an estimated 14.5% over the six months ended September 30, 2025, driven primarily by growth in oral nicotine pouches.
• Helix began commercializing on! PLUS in October 2025, following the expiration of the 180-day statutory review period for its PMTA, indicating progress in the smoke-free portfolio.
• PM USA and Middleton implemented multiple price increases across their cigarette and cigar brands in 2025, contributing to revenue management.
• USSTC and Helix implemented multiple price increases across their oral tobacco brands in 2025.
• The $3.0 billion senior unsecured 5-year revolving credit agreement was extended from October 24, 2028, to October 24, 2029, enhancing liquidity and financial flexibility.
• Canadian class actions against Altria and PM USA will be dismissed as part of a CAD $32.5 billion global settlement by other Canadian tobacco manufacturers, with Altria and PM USA indemnified, resolving significant litigation exposure.

Negatives

• Reported net earnings decreased by 29.1% and diluted EPS decreased by 27.4% for the nine months ended September 30, 2025, primarily due to a significant e-vapor goodwill impairment.
• Net revenues decreased by 3.4% for the nine months and 3.0% for the three months, driven by lower shipment volumes.
• A non-cash goodwill impairment of $873 million was recorded for the e-vapor reporting unit in Q1 2025, reflecting challenges in the NJOY business.
• Domestic cigarette shipment volume decreased by an estimated 10.5% (adjusted) for the nine months and 9% (adjusted) for the three months, indicating continued decline in the core business.
• Oral tobacco products segment net revenues decreased by 4.6% for the three months, impacted by lower volume/mix.
• On! nicotine pouch share of the nicotine pouch category decreased by 2.1 share points to 16.6% for the nine months and 4.1 share points to 15.6% for the three months, indicating market share loss in a growing category.
• The U.S. International Trade Commission (ITC) issued an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States, effective March 31, 2025, severely impacting NJOY's flagship product.
• The U.S. District Court for the Eastern District of Virginia ruled in favor of the IRS regarding foreign attribution rules, leading to a $310 million reserve for 2018-2025 tax years and a $77 million increase to a valuation allowance, creating a significant tax liability.
• Discretionary income pressures on adult tobacco consumers, inflation, and tariffs have negatively impacted sales volumes of premium brands and contributed to increased discount brand share performance.
• Illicit flavored disposable e-vapor products, many believed to have evaded the regulatory process, represent more than 60% of the e-vapor category, posing a significant competitive threat to lawful products.
• Income from the equity investment in ABI was lower due to the 2024 ABI Transaction and a lower ownership interest, despite the fair value of the investment exceeding its carrying value.

Risks

• Inability to anticipate and respond to changes in adult tobacco consumer preferences and purchase behavior.
• Inability to compete effectively, particularly against the growth of illicit disposable e-vapor products.
• Impact of illicit trade in tobacco products and the sale of products designed to avoid the regulatory framework for tobacco products.
• Failure to develop and commercialize innovative products, including tobacco products that may reduce health risks and appeal to adult tobacco consumers.
• Changes in macroeconomic and geopolitical conditions (including inflation and tariffs) that result in shifts in adult tobacco consumer disposable income and purchasing behavior, leading to lower-priced and discount brands or products, and reductions in shipment volumes.
• Unfavorable outcomes with respect to litigation proceedings or any governmental investigations, including significant monetary and non-monetary remedies and importation bans.
• Risks associated with significant federal, state, and local government actions, including FDA regulatory actions and inaction (e.g., potential product standards for nicotine in combustibles, flavor bans).
• Risk that regulators, including the FDA, and courts may interpret laws, rules, and regulations applicable to products differently than the company does.
• Increases in tobacco product-related taxes.
• Failure to complete or manage successfully strategic relationships or transactions, including acquisitions, dispositions, joint ventures, and investments in third parties, or realize the anticipated benefits of such transactions.
• Significant changes in price, availability, or quality of tobacco, other raw materials, or component parts, including as a result of changes in macroeconomic, climate, and geopolitical conditions.
• Reliance on a few significant facilities and a small number of key suppliers, distributors, and distribution chain service providers, and the risks associated with an extended disruption.
• Risk that the company may be required to write down goodwill and intangible assets, including trademarks and other intellectual property, due to impairment.
• Risks associated with the 'Optimize & Accelerate' Initiative, including business continuity, internal control over financial reporting, and the ability to recognize expected savings.
• Risk that the company could decide, or be required, to recall products.
• Various risks related to health epidemics and pandemics and the measures that international, federal, state, and local governments implement to address them.
• Inability to attract and retain a highly skilled workforce due to the decreasing social acceptance of tobacco usage, tobacco control actions, and other factors.
• Risks associated with various U.S. and foreign laws and regulations due to international business operations.
• Risks concerning a challenge to tax positions, an increase in the income tax rate, or other changes to federal or state tax laws.
• Risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters.
• Disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets.
• A downgrade or potential downgrade of credit ratings.
• The impact of heightened focus by investors and other stakeholders on performance relating to corporate responsibility matters.
• The failure of the company's, or its key service providers' or key suppliers', information systems to function as intended, or cyber-attacks or security breaches.
• Failure to comply with laws related to personal data protection, privacy, artificial intelligence, and information security.
• The risk that the expected benefits of the investment in ABI may not materialize in the expected manner or timeframe or at all.
• The risks associated with the investment in Cronos, including legal, regulatory, and reputational risks and the risk that the expected benefits of the transaction may not materialize.

Future Outlook

Altria maintains a progressive dividend goal targeting mid-single digits dividend growth annually through 2028. The company anticipates making additional employer contributions of up to approximately $5 million to its pension plans in 2025. The 'Optimize & Accelerate' Initiative's design and detailed plans are expected to be substantially complete in early 2026, with total pre-tax charges estimated at approximately $125 million. The company expects an initial determination from the ALJ in September 2026 and an ITC final determination in January 2027 for JUUL's patent infringement action against NJOY Daily. An evidentiary hearing for R.J. Reynolds' motion to vacate the ALCS judgment is set for February 2026.

Management Comments

• "We are Moving Beyond Smoking, by responsibly transitioning adult smokers to a smoke-free future, competing vigorously for existing smoke-free adult nicotine consumers and exploring new growth opportunities beyond the United States and beyond nicotine."
• "We believe that the estimated fair value of the e-vapor reporting unit at March 31, 2025 remains reasonable and there are no events or circumstances indicating an impairment for the three months ended September 30, 2025."
• "If the assumptions or judgments regarding the expectations for the future state of the e-vapor category and NJOYs business discussed above fail to materialize as anticipated, if we experience unfavorable outcomes with respect to litigation proceedings (including actions alleging patent infringement), or if the discount rate used to estimate the fair value increases, we could have additional non-cash impairments of our e-vapor reporting unit goodwill in future periods, which could be material."
• "We believe that the estimated fair value of the Skoal trademark at December 31, 2024 remains reasonable and there are no events or circumstances indicating an impairment for the three months ended September 30, 2025."
• "If Skoal's actual revenue and income or long-term outlook are significantly unfavorable compared to forecasted performance used to estimate the fair value or if the discount rate used to estimate the fair value increases, we could have material non-cash impairments of the Skoal trademark in future periods."
• "We believe our cash and cash equivalents balance, along with our future cash flows from operations, capacity for borrowings under our Credit Agreement and access to credit and capital markets, provide sufficient liquidity to meet the needs of our business operations and to satisfy our projected cash requirements for the foreseeable future, including the next 12 months."
• "We believe, and have been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts. We have defended, and will continue to defend, vigorously against litigation challenges. However, we may enter into settlement discussions in particular cases if we believe it is in our best interests to do so."

Industry Context

The U.S. tobacco industry is facing significant challenges, including inflationary pressures on adult tobacco consumers' discretionary income, leading to increased demand for discount brands. The e-vapor category is experiencing rapid growth, largely driven by illicit flavored disposable products that evade regulatory oversight, posing a competitive threat to authorized products. The U.S. nicotine pouch category continues its strong growth, indicating a broader consumer shift towards smoke-free alternatives, which negatively impacts traditional cigarette and moist smokeless tobacco (MST) volumes. Regulatory actions by the FDA, including potential product standards for nicotine in combustibles and flavor bans, along with increasing excise taxes, are creating an uncertain and challenging operating environment. Geopolitical and macroeconomic conditions, including tariffs, are also impacting supply chains and raw material costs.

Comparison to Industry Standards

• The total estimated domestic cigarette industry volume declined by an estimated 8% in the third quarter of 2025, while PM USA's domestic cigarette shipment volume declined by an estimated 9% (adjusted), indicating a slightly worse performance than the industry average.
• The discount share of the cigarette category reached 32.2% in Q3 2025, an increase of 2.4 share points versus Q3 2024, reflecting a broader industry trend of consumers shifting to lower-priced options due to economic pressures.
• The U.S. nicotine pouch category grew to 55.7% of the U.S. oral tobacco category in Q3 2025, an increase of 11.1 share points year-over-year, highlighting strong industry growth in this segment.
• Altria's on! brand's share of the nicotine pouch category decreased by 2.1 share points to 16.6% for the nine months and 4.1 share points to 15.6% for the three months, suggesting underperformance relative to the overall category growth.
• The CAD $32.5 billion global settlement by other Canadian tobacco manufacturers for tobacco product-related claims provides a benchmark for the scale of tobacco-related litigation, from which Altria and PM USA are released due to indemnification obligations.

Legal Proceedings

• **NJOY ACE Patent Infringement (JUUL/VMR vs. Altria/NJOY):** The ITC issued exclusion and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the U.S., effective March 31, 2025. Altria is appealing this determination to the U.S. Court of Appeals for the Federal Circuit.
• **NJOY Patent Validity Challenges (JUUL vs. NJOY):** The PTAB upheld the validity of NJOY's patents that were challenged by JUUL.
• **NJOY vs. JUUL Patent Infringement:** NJOY filed a lawsuit in the U.S. District Court for the District of Delaware and a related ITC action against JUUL for patent infringement of JUUL products. The ITC affirmed non-infringement, and Altria voluntarily dismissed its appeal to lift the stay on the District Court lawsuit.
• **JUUL vs. Altria/NJOY Daily Patent Infringement:** JUUL filed new lawsuits in the U.S. District Court for the District of Arizona and with the ITC alleging patent infringement by NJOY Daily. A hearing is scheduled for April 2026, with an initial determination expected in September 2026 and a final ITC determination in January 2027.
• **Perez-Trinidad (Massachusetts State Court):** A jury returned a verdict in favor of the plaintiff, awarding $1 million in compensatory damages against PM USA and R.J. Reynolds, and $5.5 million in punitive damages against PM USA. PM USA intends to file post-trial motions and, if necessary, will appeal.
• **Amaral (Massachusetts State Court):** A jury returned a verdict in favor of the plaintiff, awarding $4 million in compensatory damages against PM USA and R.J. Reynolds, and $25 million in punitive damages against PM USA. PM USA has filed post-trial motions and will appeal if necessary.
• **Ricapor-Hall (Hawaii State Court):** A judgment was entered against PM USA for $11 million ($3 million compensatory, $8 million punitive). PM USA's appeal remains pending, and the plaintiff has noticed a cross-appeal.
• **Fontaine (Massachusetts State Court):** A final judgment was entered awarding the plaintiff $8 million in compensatory damages and $56 million in punitive damages (reduced from $1 billion). PM USA's appeal is pending before the Massachusetts Supreme Judicial Court.
• **Federal Government Lawsuit (RICO):** The district court held in August 2006 that certain defendants, including Altria and PM USA, violated RICO and engaged in sub-schemes to defraud, ordering various non-monetary relief, including corrective statements. A consent order for corrective statements on point-of-sale signage was approved in December 2022.
• **Engle Progeny Cases (Florida):** Approximately 51 state court cases are pending against PM USA or Altria asserting individual claims. As of October 27, 2025, 147 federal and state Engle progeny cases involving PM USA have resulted in verdicts, with 88 in favor of plaintiffs (four reversed) and 59 in favor of PM USA (one reversed).
• **Garcia (Miami-Dade):** A jury awarded $2 million in compensatory damages and $10 million in punitive damages against PM USA. Appeals to the Third District Court of Appeal are pending.
• **Chacon (Miami-Dade):** A jury awarded less than $1 million in compensatory damages and less than $1 million in punitive damages against PM USA. Appeals to the Third District Court of Appeal are pending.
• **Lipp (Miami-Dade):** A jury awarded $15 million in compensatory damages and $28 million in punitive damages against PM USA. The Third District Court of Appeal reversed and remanded for a new trial.
• **McCall (Broward):** A jury awarded less than $1 million in compensatory damages and less than $1 million in punitive damages against PM USA. An appeal to the Fourth District Court of Appeal is pending.
• **Canadian Class Actions:** Seven smoking and health class actions and 10 health care cost recovery actions are pending against PM USA and/or Altria in various Canadian provinces. These cases will be dismissed as part of a CAD $32.5 billion global settlement by other Canadian tobacco manufacturers, with Altria and PM USA indemnified under the Distribution Agreement.
• **Broin Flight Attendant Litigation:** An agreement was reached to resolve approximately 627 individual Broin lawsuits for $4 million, which was paid in the third quarter of 2024. One individual case remains pending.
• **NPM Adjustment Disputes:** Ongoing arbitrations and legal challenges with states that have not settled the Non-Participating Manufacturer (NPM) Adjustment disputes (e.g., Washington, Missouri, New Mexico, Maryland, Wisconsin, Ohio).
• **Mississippi State Settlement Agreement:** PM USA and the State of Mississippi settled their dispute over profit adjustment payments, with PM USA paying $7 million.
• **Texas State Settlement Agreement:** The court found that PM USA owes $31 million to the State of Texas, plus preand post-judgment interest. PM USA has appealed this decision.
• **Minnesota State Settlement Agreement:** The court found that PM USA owes the State of Minnesota $10 million plus pre-judgment and post-judgment interest. PM USA intends to appeal.
• **Graphic Warnings Rule (FDA):** Multiple lawsuits are challenging the FDA's final rule requiring graphic warnings on cigarette packaging and advertising. Decisions have varied, with some courts blocking the rule and others reversing those decisions, leading to ongoing appeals.
• **Antitrust Litigation (Altria/JUUL):** 17 putative class action lawsuits have been consolidated into three complaints against Altria and JUUL, alleging violations of the Sherman and Clayton Antitrust Acts. The trial for the remaining claims is set to commence in May 2026.
• **Shareholder Derivative Lawsuits (JUUL-related):** A series of federal and state derivative cases brought by Altria shareholders related to the former investment in JUUL were settled, with Altria agreeing to provide $100 million in funding over five years to underage tobacco prevention and cessation programs.
• **Illicit E-vapor Products Lawsuit (California):** Altria settled a lawsuit against manufacturers, distributors, and retailers of illicit e-vapor products, resulting in a prohibition on selling or shipping flavored e-vapor products to consumers, retailers, wholesalers, or distributors in California.

Related Party Transactions

• Altria holds an approximate 8.1% ownership interest in Anheuser-Busch InBev SA/NV (ABI), which is accounted for under the equity method.
• Altria holds an approximate 40.9% ownership interest in Cronos Group Inc. (Cronos), which is accounted for under the equity method.
• Under a distribution agreement with Philip Morris International Inc. (PMI), liabilities concerning tobacco products are allocated based on the manufacturer, with PMI indemnifying Altria and PM USA for certain liabilities and vice versa.
• Altria guarantees the financial obligations of ALCS under a supplier financing program agreement.
• Philip Morris USA Inc. (PM USA) guarantees Altria's obligations under its outstanding debt securities, borrowings under its $3.0 billion Credit Agreement, and any amounts outstanding under its commercial paper program.

Stakeholder Impact

• **Shareholders:** Impacted by decreased reported earnings, increased dividend payments, expanded share repurchase program, and ongoing litigation and regulatory risks that could affect future returns.
• **Employees:** Affected by the 'Optimize & Accelerate' Initiative, which involves centralizing work, outsourcing tasks, and streamlining processes, potentially leading to employee separations and associated costs.
• **Customers (Adult Tobacco Consumers):** Impacted by pricing actions, product availability (e.g., NJOY ACE import ban), and evolving product preferences, including a shift towards smoke-free products and discount brands due to economic pressures.
• **Suppliers:** Potential impact from changes in demand for raw materials and component parts due to shifts in product categories (e.g., decline in combustible/MST products) and macroeconomic conditions, which could affect supply and availability.
• **Creditors:** Impacted by the company's debt levels, credit ratings, and guarantees provided by PM USA, which underpin the company's ability to access capital markets.
• **Regulatory Bodies:** Ongoing engagement and challenges with the FDA, IRS, and various state attorneys general regarding product regulation, tax matters, and litigation, influencing the company's operating environment and compliance costs.

Next Steps

• Continue to appeal the ITC's exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE.
• Continue to pursue all available appellate remedies for the U.S. District Court ruling in favor of the IRS regarding foreign attribution rules.
• Perform annual impairment testing during the fourth quarter of 2025.
• Further develop and finalize detailed plans for additional phases of the 'Optimize & Accelerate' Initiative, with design and detailed plans expected to be substantially complete in early 2026.
• Continue to make employer contributions to pension plans (up to $5 million anticipated in 2025).
• Continue to commercialize on! PLUS following the expiration of the 180-day statutory review period.
• Engage with the FDA through the rulemaking process for the proposed product standard on nicotine levels in combustible tobacco products.
• Monitor the impact of increased inflation on the macroeconomic environment and businesses.
• Continue to defend vigorously against litigation challenges, potentially entering into settlement discussions if in the best interest.
• Appeal the Minnesota court's order regarding profit adjustment payments.
• Prepare for the evidentiary hearing in February 2026 regarding R.J. Reynolds' motion to vacate ALCS judgment.
• Prepare for the hearing before the ALJ in April 2026 for JUUL's patent infringement action against NJOY Daily.
• Evaluate the impact of new accounting guidance (ASU Nos. 2023-09, 2024-03, 2025-01, 2025-05, 2025-06, 2025-07) on financial statements and disclosures.

Key Dates

Recommendation

The significant decline in reported net earnings due to the e-vapor goodwill impairment and the NJOY ACE import ban are major concerns, highlighting the challenges in the evolving smoke-free category. While adjusted earnings show growth and the company maintains a strong dividend and share repurchase program, the core combustible business faces declining volumes, and the oral tobacco segment shows mixed performance with market share losses in nicotine pouches. The ongoing regulatory and litigation landscape, including the adverse tax ruling, adds considerable uncertainty. Given the mixed financial performance, strategic challenges in next-generation products, and persistent regulatory headwinds, a 'Hold' recommendation is appropriate for investors to monitor the company's ability to execute its 'Moving Beyond Smoking' vision and navigate these complex issues.

Keywords

Altria, MO, SEC Filing, 10-Q, Quarterly Report, Earnings, EPS, Net Revenue, Operating Income, Goodwill Impairment, E-vapor, NJOY, Cigarettes, Marlboro, Oral Tobacco, Nicotine Pouches, on!, Dividend, Share Repurchase, Litigation, FDA Regulation, Tobacco Industry, Smoke-free Products, Financial Performance, Risk Factors